 | • レポートコード：QY2108PAL8780 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の当調査資料ではグローバルにおけるバイオシミラーモノクローナル抗体の市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、バイオシミラーモノクローナル抗体の種類別市場規模（インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、その他）、用途別市場規模（腫瘍学、自己免疫疾患、その他）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界のバイオシミラーモノクローナル抗体市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界におけるバイオシミラーモノクローナル抗体の種類別市場規模（2016年-2027年）：インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、その他 ・世界におけるバイオシミラーモノクローナル抗体の用途別市場規模（2016年-2027年）：腫瘍学、自己免疫疾患、その他 ・バイオシミラーモノクローナル抗体の中国市場分析 - バイオシミラーモノクローナル抗体の中国市場規模（2016年-2027年） - 中国におけるバイオシミラーモノクローナル抗体の主要プレイヤー別市場シェア - 中国におけるバイオシミラーモノクローナル抗体の種類別市場規模：インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、その他 - 中国におけるバイオシミラーモノクローナル抗体の用途別市場規模：腫瘍学、自己免疫疾患、その他 ・バイオシミラーモノクローナル抗体の北米市場（2016年-2027年） ・バイオシミラーモノクローナル抗体のヨーロッパ市場（2016年-2027年） ・バイオシミラーモノクローナル抗体のアジア太平洋市場（2016年-2027年） ・バイオシミラーモノクローナル抗体の中南米市場（2016年-2027年） ・バイオシミラーモノクローナル抗体の中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：Celltrion、Pfizer (Hospira)、3SBIO、Novartis (Sandoz)、Dr Reddy’s、Celgen Biopharma、Cadila Healthcare、Hisun Pharma、Torrent Pharmaceuticals ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・... |
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Market Analysis and Insights: Global and China Biosimilar Monoclonal Antibodies Market
This report focuses on global and China Biosimilar Monoclonal Antibodies market.
In 2020, the global Biosimilar Monoclonal Antibodies market size was US$ 3666 million and it is expected to reach US$ 27030 million by the end of 2027, with a CAGR of 33.2% during 2021-2027. In China the Biosimilar Monoclonal Antibodies market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Biosimilar Monoclonal Antibodies Scope and Market Size
Biosimilar Monoclonal Antibodies market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Biosimilar Monoclonal Antibodies market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
1 Study Coverage
1.1 Biosimilar Monoclonal Antibodies Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Market by Application
1.3.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application
1.3.2 Oncology
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biosimilar Monoclonal Antibodies Market Size, Estimates and Forecasts
2.1.1 Global Biosimilar Monoclonal Antibodies Revenue 2016-2027
2.1.2 Global Biosimilar Monoclonal Antibodies Sales 2016-2027
2.2 Global Biosimilar Monoclonal Antibodies, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Biosimilar Monoclonal Antibodies Historical Market Size by Region (2016-2021)
2.3.1 Global Biosimilar Monoclonal Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Biosimilar Monoclonal Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Biosimilar Monoclonal Antibodies Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Region (2022-2027)
2.4.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Region (2022-2027)
3 Global Biosimilar Monoclonal Antibodies Competitor Landscape by Players
3.1 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Sales
3.1.1 Global Biosimilar Monoclonal Antibodies Sales by Manufacturer (2016-2021)
3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Revenue
3.2.1 Key Biosimilar Monoclonal Antibodies Manufacturers Covered: Ranking by Revenue
3.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2021)
3.2.3 Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Biosimilar Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibodies Revenue in 2020
3.2.6 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Biosimilar Monoclonal Antibodies Price by Manufacturers
3.4 Global Biosimilar Monoclonal Antibodies Manufacturing Base Distribution, Product Types
3.4.1 Biosimilar Monoclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biosimilar Monoclonal Antibodies Product Type
3.4.3 Date of International Manufacturers Enter into Biosimilar Monoclonal Antibodies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Biosimilar Monoclonal Antibodies Market Size by Type (2016-2021)
4.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2016-2021)
4.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2016-2021)
4.1.3 Biosimilar Monoclonal Antibodies Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Biosimilar Monoclonal Antibodies Market Size Forecast by Type (2022-2027)
4.2.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Type (2022-2027)
4.2.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Type (2022-2027)
4.2.3 Biosimilar Monoclonal Antibodies Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Biosimilar Monoclonal Antibodies Market Size by Application (2016-2021)
5.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2016-2021)
5.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2016-2021)
5.1.3 Biosimilar Monoclonal Antibodies Price by Application (2016-2021)
5.2 Biosimilar Monoclonal Antibodies Market Size Forecast by Application (2022-2027)
5.2.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Application (2022-2027)
5.2.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Application (2022-2027)
5.2.3 Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
6.1.1 China Biosimilar Monoclonal Antibodies Sales YoY Growth 2016-2027
6.1.2 China Biosimilar Monoclonal Antibodies Revenue YoY Growth 2016-2027
6.1.3 China Biosimilar Monoclonal Antibodies Market Share in Global Market 2016-2027
6.2 China Biosimilar Monoclonal Antibodies Market Size by Players (International and Local Players)
6.2.1 China Top Biosimilar Monoclonal Antibodies Players by Sales (2016-2021)
6.2.2 China Top Biosimilar Monoclonal Antibodies Players by Revenue (2016-2021)
6.3 China Biosimilar Monoclonal Antibodies Historic Market Review by Type (2016-2021)
6.3.1 China Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
6.3.2 China Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
6.3.3 China Biosimilar Monoclonal Antibodies Price by Type (2016-2021)
6.4 China Biosimilar Monoclonal Antibodies Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Biosimilar Monoclonal Antibodies Sales Forecast by Type (2022-2027)
6.4.2 China Biosimilar Monoclonal Antibodies Revenue Forecast by Type (2022-2027)
6.4.3 China Biosimilar Monoclonal Antibodies Price Forecast by Type (2022-2027)
6.5 China Biosimilar Monoclonal Antibodies Historic Market Review by Application (2016-2021)
6.5.1 China Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
6.5.2 China Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
6.5.3 China Biosimilar Monoclonal Antibodies Price by Application (2016-2021)
6.6 China Biosimilar Monoclonal Antibodies Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Biosimilar Monoclonal Antibodies Sales Forecast by Application (2022-2027)
6.6.2 China Biosimilar Monoclonal Antibodies Revenue Forecast by Application (2022-2027)
6.6.3 China Biosimilar Monoclonal Antibodies Price Forecast by Application (2022-2027)
7 North America
7.1 North America Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
7.2 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
7.2.1 North America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
7.2.2 North America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
8.2 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Region
8.2.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2016-2021)
8.2.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
9.2 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
9.2.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
9.2.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
10.2 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
10.2.1 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
10.2.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
11.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
11.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Celltrion
12.1.1 Celltrion Corporation Information
12.1.2 Celltrion Description and Business Overview
12.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Celltrion Biosimilar Monoclonal Antibodies Products Offered
12.1.5 Celltrion Recent Development
12.2 Pfizer (Hospira)
12.2.1 Pfizer (Hospira) Corporation Information
12.2.2 Pfizer (Hospira) Description and Business Overview
12.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Products Offered
12.2.5 Pfizer (Hospira) Recent Development
12.3 3SBIO
12.3.1 3SBIO Corporation Information
12.3.2 3SBIO Description and Business Overview
12.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.3.4 3SBIO Biosimilar Monoclonal Antibodies Products Offered
12.3.5 3SBIO Recent Development
12.4 Novartis (Sandoz)
12.4.1 Novartis (Sandoz) Corporation Information
12.4.2 Novartis (Sandoz) Description and Business Overview
12.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Products Offered
12.4.5 Novartis (Sandoz) Recent Development
12.5 Dr Reddy’s
12.5.1 Dr Reddy’s Corporation Information
12.5.2 Dr Reddy’s Description and Business Overview
12.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Products Offered
12.5.5 Dr Reddy’s Recent Development
12.6 Celgen Biopharma
12.6.1 Celgen Biopharma Corporation Information
12.6.2 Celgen Biopharma Description and Business Overview
12.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Products Offered
12.6.5 Celgen Biopharma Recent Development
12.7 Cadila Healthcare
12.7.1 Cadila Healthcare Corporation Information
12.7.2 Cadila Healthcare Description and Business Overview
12.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Products Offered
12.7.5 Cadila Healthcare Recent Development
12.8 Hisun Pharma
12.8.1 Hisun Pharma Corporation Information
12.8.2 Hisun Pharma Description and Business Overview
12.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Products Offered
12.8.5 Hisun Pharma Recent Development
12.9 Torrent Pharmaceuticals
12.9.1 Torrent Pharmaceuticals Corporation Information
12.9.2 Torrent Pharmaceuticals Description and Business Overview
12.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Products Offered
12.9.5 Torrent Pharmaceuticals Recent Development
12.11 Celltrion
12.11.1 Celltrion Corporation Information
12.11.2 Celltrion Description and Business Overview
12.11.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Celltrion Biosimilar Monoclonal Antibodies Products Offered
12.11.5 Celltrion Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Biosimilar Monoclonal Antibodies Industry Trends
13.2 Biosimilar Monoclonal Antibodies Market Drivers
13.3 Biosimilar Monoclonal Antibodies Market Challenges
13.4 Biosimilar Monoclonal Antibodies Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biosimilar Monoclonal Antibodies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Infliximab
Table 3. Major Manufacturers of Rituximab
Table 4. Major Manufacturers of Trastuzumab
Table 5. Major Manufacturers of Adalimumab
Table 6. Major Manufacturers of Other
Table 7. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 8. Global Biosimilar Monoclonal Antibodies Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 9. Global Biosimilar Monoclonal Antibodies Sales by Regions (2016-2021) & (K Units)
Table 10. Global Biosimilar Monoclonal Antibodies Sales Market Share by Regions (2016-2021)
Table 11. Global Biosimilar Monoclonal Antibodies Revenue by Regions (2016-2021) & (US$ Million)
Table 12. Global Biosimilar Monoclonal Antibodies Sales Forecast by Region (2022-2027) & (K Units)
Table 13. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Region (2022-2027)
Table 14. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 15. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Region (2022-2027)
Table 16. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2021) (K Units)
Table 17. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturers (2016-2021)
Table 18. Ranking of Global Top Biosimilar Monoclonal Antibodies Manufacturers by Revenue (US$ Million) in 2020
Table 19. Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2021) (US$ Million)
Table 20. Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2016-2021)
Table 21. Global Biosimilar Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 22. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2020)
Table 23. Key Manufacturers Biosimilar Monoclonal Antibodies Price (2016-2021) (USD/Unit)
Table 24. Biosimilar Monoclonal Antibodies Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Biosimilar Monoclonal Antibodies Product Type
Table 26. Date of International Manufacturers Enter into Biosimilar Monoclonal Antibodies Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) (K Units)
Table 29. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2016-2021)
Table 30. Global Biosimilar Monoclonal Antibodies Revenue by Type (2016-2021) (US$ Million)
Table 31. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2016-2021)
Table 32. Biosimilar Monoclonal Antibodies Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 33. Global Biosimilar Monoclonal Antibodies Sales Forecast by Type (2022-2027) & (K Units)
Table 34. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Type (2022-2027)
Table 35. Global Biosimilar Monoclonal Antibodies Revenue Forecast V (2022-2027) & (US$ Million)
Table 36. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Type (2022-2027)
Table 37. Global Biosimilar Monoclonal Antibodies Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 38. Global Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) (K Units)
Table 39. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2016-2021)
Table 40. Global Biosimilar Monoclonal Antibodies Revenue by Application (2016-2021) (US$ Million)
Table 41. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2016-2021)
Table 42. Biosimilar Monoclonal Antibodies Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 43. Global Biosimilar Monoclonal Antibodies Sales Forecast by Application (2022-2027) & (K Units)
Table 44. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Application (2022-2027)
Table 45. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 46. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Application (2022-2027)
Table 47. Global Biosimilar Monoclonal Antibodies Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 48. China Biosimilar Monoclonal Antibodies Sales (K Units) of Key Companies (2016-2021)
Table 49. China Biosimilar Monoclonal Antibodies Sales Share by Company (2016-2021)
Table 50. China Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Company (2016-2021)
Table 51. China Biosimilar Monoclonal Antibodies Revenue Share by Company (2016-2021)
Table 52. China Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2016-2021)
Table 53. China Biosimilar Monoclonal Antibodies Sales Share by Type (2016-2021)
Table 54. China Biosimilar Monoclonal Antibodies Revenue (US$ Million) Market Share by Type (2016-2021)
Table 55. China Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2016-2021)
Table 56. China Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2022-2027)
Table 57. China Biosimilar Monoclonal Antibodies Sales Share by Type (2022-2027)
Table 58. China Biosimilar Monoclonal Antibodies Revenue (US$ Million) Market Share by Type (2022-2027)
Table 59. China Biosimilar Monoclonal Antibodies Revenue Share by Type (2022-2027)
Table 60. China Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2022-2027)
Table 61. China Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2016-2021)
Table 62. China Biosimilar Monoclonal Antibodies Sales Share by Application (2016-2021)
Table 63. China Biosimilar Monoclonal Antibodies Revenue (US$ Million) Market Share by Application (2016-2021)
Table 64. China Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2016-2021)
Table 65. China Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2022-2027)
Table 66. China Biosimilar Monoclonal Antibodies Sales Share by Application (2022-2027)
Table 67. China Biosimilar Monoclonal Antibodies Revenue (US$ Million) Market Share by Application (2022-2027)
Table 68. China Biosimilar Monoclonal Antibodies Revenue Share by Application (2022-2027)
Table 69. China Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2022-2027)
Table 70. North America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 71. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 72. North America Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 73. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 74. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2016-2021) & (K Units)
Table 75. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Table 76. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021) & (US$ Million)
Table 77. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Table 78. Europe Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 79. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 80. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 81. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 82. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 83. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 84. Latin Americaa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 85. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 86. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 87. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 88. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & (US$ Million)
Table 89. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 90. Celltrion Corporation Information
Table 91. Celltrion Description and Business Overview
Table 92. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 93. Celltrion Biosimilar Monoclonal Antibodies Product
Table 94. Celltrion Recent Development
Table 95. Pfizer (Hospira) Corporation Information
Table 96. Pfizer (Hospira) Description and Business Overview
Table 97. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 98. Pfizer (Hospira) Product
Table 99. Pfizer (Hospira) Recent Development
Table 100. 3SBIO Corporation Information
Table 101. 3SBIO Description and Business Overview
Table 102. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. 3SBIO Product
Table 104. 3SBIO Recent Development
Table 105. Novartis (Sandoz) Corporation Information
Table 106. Novartis (Sandoz) Description and Business Overview
Table 107. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 108. Novartis (Sandoz) Product
Table 109. Novartis (Sandoz) Recent Development
Table 110. Dr Reddy’s Corporation Information
Table 111. Dr Reddy’s Description and Business Overview
Table 112. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Dr Reddy’s Product
Table 114. Dr Reddy’s Recent Development
Table 115. Celgen Biopharma Corporation Information
Table 116. Celgen Biopharma Description and Business Overview
Table 117. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Celgen Biopharma Product
Table 119. Celgen Biopharma Recent Development
Table 120. Cadila Healthcare Corporation Information
Table 121. Cadila Healthcare Description and Business Overview
Table 122. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Cadila Healthcare Product
Table 124. Cadila Healthcare Recent Development
Table 125. Hisun Pharma Corporation Information
Table 126. Hisun Pharma Description and Business Overview
Table 127. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Hisun Pharma Product
Table 129. Hisun Pharma Recent Development
Table 130. Torrent Pharmaceuticals Corporation Information
Table 131. Torrent Pharmaceuticals Description and Business Overview
Table 132. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Torrent Pharmaceuticals Product
Table 134. Torrent Pharmaceuticals Recent Development
Table 135. Biosimilar Monoclonal Antibodies Market Trends
Table 136. Biosimilar Monoclonal Antibodies Market Drivers
Table 137. Biosimilar Monoclonal Antibodies Market Challenges
Table 138. Biosimilar Monoclonal Antibodies Market Restraints
Table 139. Biosimilar Monoclonal Antibodies Customers List
Table 140. Biosimilar Monoclonal Antibodies Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Monoclonal Antibodies Product Picture
Figure 2. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020 & 2027
Figure 3. Infliximab Product Picture
Figure 4. Rituximab Product Picture
Figure 5. Trastuzumab Product Picture
Figure 6. Adalimumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020 & 2027
Figure 9. Oncology
Figure 10. Autoimmune Disease
Figure 11. Other
Figure 12. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 13. Global Biosimilar Monoclonal Antibodies Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Biosimilar Monoclonal Antibodies Market Size 2016-2027 (US$ Million)
Figure 15. Global Biosimilar Monoclonal Antibodies Sales 2016-2027 (K Units)
Figure 16. Global Biosimilar Monoclonal Antibodies Market Size Market Share by Region: 2021 Versus 2027
Figure 17. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Figure 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region in 2020
Figure 19. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Figure 20. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in 2020
Figure 21. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturer in 2020
Figure 22. The Top 10 and 5 Players Market Share by Biosimilar Monoclonal Antibodies Revenue in 2020
Figure 23. Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 24. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Figure 25. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 26. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
Figure 27. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type in 2020
Figure 28. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Figure 29. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020
Figure 30. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
Figure 31. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application in 2020
Figure 32. China Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2027 (K Units)
Figure 33. China Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2027 (US$ Million)
Figure 34. China Biosimilar Monoclonal Antibodies Market Share in Global Market 2016-2027
Figure 35. China 5 and 10 Largest Biosimilar Monoclonal Antibodies Players Market Share by Revenue in Biosimilar Monoclonal Antibodies in 2020
Figure 36. China Biosimilar Monoclonal Antibodies Revenue Share by Type (2016-2021)
Figure 37. China Biosimilar Monoclonal Antibodies Revenue Growth Rate by Type in 2016 & 2020
Figure 38. China Biosimilar Monoclonal Antibodies Revenue Share by Application (2016-2021)
Figure 39. China Biosimilar Monoclonal Antibodies Revenue Growth Rate by Application in 2016 & 2020
Figure 40. North America Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2021 (K Units)
Figure 41. North America Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2021 (US$ Million)
Figure 42. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 43. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 44. U.S. Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 45. U.S. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Canada Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 47. Canada Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Europe Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2021 (K Units)
Figure 49. Europe Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2021 (US$ Million)
Figure 50. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 51. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 52. Germany Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 53. Germany Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. France Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 55. France Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. U.K. Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 57. U.K. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Italy Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 59. Italy Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Russia Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 61. Russia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 62. Asia Pacific Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2021 (K Units)
Figure 63. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2021 (US$ Million)
Figure 64. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Region in 2020
Figure 65. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Region in 2020
Figure 66. China Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 67. China Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. Japan Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 69. Japan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. South Korea Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 71. South Korea Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. India Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 73. India Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. Australia Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 75. Australia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Taiwan Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 77. Taiwan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Indonesia Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 79. Indonesia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Thailand Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 81. Thailand Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Malaysia Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 83. Malaysia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 84. Philippines Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 85. Philippines Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 86. Vietnam Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 87. Vietnam Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 88. Latin America Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2021 (K Units)
Figure 89. Latin America Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2021 (US$ Million)
Figure 90. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 91. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 92. Mexico Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 93. Mexico Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 94. Brazil Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 95. Brazil Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 96. Argentina Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 97. Argentina Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 98. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2021 (K Units)
Figure 99. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2021 (US$ Million)
Figure 100. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 101. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 102. Turkey Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 103. Turkey Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 104. Saudi Arabia Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 105. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 106. U.A.E Biosimilar Monoclonal Antibodies Sales Growth Rate (2016-2021) (K Units)
Figure 107. U.A.E Biosimilar Monoclonal Antibodies Revenue Growth Rate (2016-2021) (US$ Million)
Figure 108. Biosimilar Monoclonal Antibodies Value Chain
Figure 109. Channels of Distribution
Figure 110. Distributors Profiles
Figure 111. Bottom-up and Top-down Approaches for This Report
Figure 112. Data Triangulation
Figure 113. Key Executives Interviewed